Market movers: Intel, Telus, Summit Therapeutics, Grey Matters
Grey Matters Health completed Medicare/Medicaid enrollment for a Florida clinic. Intel shares fell 6% amid a shareholder lawsuit. Telus shares rose 11% on a $21.7B takeover offer. Summit Therapeutics shares dropped 12.69% after FDA rejection. Ceres Power shares rose 8% on a new manufacturing deal.
How this was made
The 30-second read
Why it matters
Traders can act on near-term repricing driven by litigation risk (INTC), takeover bid dynamics (TU), and regulatory approval probability and timeline (SMMT).
Market read
Same-day catalysts are likely to drive continued volatility and positioning around litigation headlines, M&A deal odds, and FDA regulatory pathways.
What to watch
For Telus, deal certainty depends on financing, shareholder acceptance, and regulatory approvals; for Summit, the CRL’s stated issues (not provided here) will determine whether the setback is structural or fixable.
Background
The piece is a multi-name market-movers roundup, but it includes three distinct primary catalysts: a newly filed Intel shareholder class action, a Quebecor takeover proposal for Telus, and an FDA complete response letter for Summit Therapeutics.
Ticker impact
Intel shares fell nearly 6% after a proposed class action alleged it concealed weakening PC demand impacts on its business.
Likely further pressure as investors price litigation risk and potential disclosure/liability exposure.
The article ties a same-day ~6% drop to a newly filed shareholder class action, which can drive near-term risk-off positioning even without a settlement.
Telus shares jumped over 11% after Quebecor proposed a cash-and-stock takeover valued around C$31 billion.
Likely sustained bid-driven strength while markets assess takeover odds and regulatory/timing risks.
The article reports a concrete takeover offer with stated consideration per share and a large premium implied by the move.
Summit Therapeutics shares dropped about 12.7% after the FDA issued a complete response letter for ivonescimab plus chemotherapy.
Likely continued downside or high volatility as investors reassess timelines and probability of approval.
A same-day FDA complete response letter is a direct, primary regulatory catalyst that typically resets expectations for approval timing.
Market effects
Intel litigation risk can weigh on broader semiconductor sentiment tied to PC-cycle demand; FDA setbacks can pressure biotech risk appetite; telecom M&A can spur deal speculation.
Canadian telecom M&A optimism supports Canadian-listed sentiment via Telus; US biotech regulatory news can spill into broader US small/mid-cap healthcare risk.
Cross-border M&A (Quebecor-Telus) highlights ongoing consolidation in telecoms; regulatory outcomes reinforce global biotech approval risk.
Counterpoint
Intel’s move may be over-discounting litigation risk absent a definitive finding, and Summit’s CRL could still lead to a workable resubmission plan depending on the CRL’s specific deficiencies.
Key entities
- US-listed equityIntel Corp
Shares fell nearly 6% on a proposed shareholder class action alleging concealed impacts from weakening PC demand.
- US-listed equityTelus Corp
Shares rose over 11% after Quebecor proposed a cash-and-stock takeover valued around C$31 billion.
- US-listed equitySummit Therapeutics PLC
Shares fell about 12.7% after the FDA issued a complete response letter for ivonescimab plus chemotherapy.




